fbpx

Day

december 8, 2015
Ness Ziona, Israel - Dec 7, 2015 - Atox Bio, developer of immunomodulatory therapeutics for rapidly-progressing infectious diseases in critically ill patients, today announced that it has enrolled the first patient in its Phase 3 study to evaluate AB103 - the first-ever candidate developed for the treatment of Necrotizing Soft Tissue Infections (NSTIs), also known...

Nyheder

Lundbeckfonden
Hjernesygdomme koster samfundet mindst 39 mia. kroner
18. november 2020
Danske forskere leverer beviset: Kejsersnit kan lede til astma og allergi
12. november 2020
En helt ny slags ’antabus’ – men mod kokainmisbrug
10. november 2020

Lundbeckfonden

Lundbeckfonden Ventures

Lundbeckfonden Emerge